Results 61 to 70 of about 1,251,677 (333)

Role of growth factors in the pathogenesis of tissue fibrosis in systemic sclerosis. [PDF]

open access: yes, 2010
The most severe clinical and pathologic manifestations of systemic sclerosis (SSc) are the result of a fibrotic process characterized by the excessive and often progressive deposition of collagen and other connective tissue macromolecules in skin and ...
Castro, Susan V.   +2 more
core   +2 more sources

The Levels of Tissue Factor Pathway Inhibitor in Sepsis Patients Receiving Prophylactic Enoxaparin

open access: yesTurkish Journal of Hematology, 2016
INTRODUCTION: Sepsis syndrome is usually accompanied by activation of blood coagulation mechanisms. Earlier studies found deficiencies of the 3 main natural anticoagulants, antithrombin, protein C, and protein S.
Hadil A Al Otair   +8 more
doaj   +1 more source

Reduced prothrombinase inhibition by tissue factor pathway inhibitor contributes to the factor V Leiden hypercoagulable state

open access: yesBlood Advances, 2017
: Activated factor V (FVa) and factor X (FXa) form prothrombinase, which converts prothrombin to thrombin. The α isoform of tissue factor pathway inhibitor (TFPI) dampens early procoagulant events, partly by interacting with FV.
Jeremy P. Wood   +4 more
doaj   +1 more source

Amphetamines induce tissue factor and impair tissue factor pathway inhibitor: role of dopamine receptor type 4 [PDF]

open access: yes, 2017
Aims Amphetamine intake is associated with acute vascular syndromes. Since these events are caused by arterial thrombosis and this in turn is triggered by tissue factor (TF), this study examines whether amphetamines regulate TF in human endothelial cells.
Akhmedov, Alexander   +6 more
core  

From omics to AI—mapping the pathogenic pathways in type 2 diabetes

open access: yesFEBS Letters, EarlyView.
Integrating multi‐omics data with AI‐based modelling (unsupervised and supervised machine learning) identify optimal patient clusters, informing AI‐driven accurate risk stratification. Digital twins simulate individual trajectories in real time, guiding precision medicine by matching patients to targeted therapies.
Siobhán O'Sullivan   +2 more
wiley   +1 more source

The nicotinamide hypothesis revisited—plant defense signaling integrating PARP, nicotinamide, nicotinic acid, epigenetics, and glutathione

open access: yesFEBS Letters, EarlyView.
Nicotinamide (NIC) and nicotinic acid (NIA) are proposed as stress signaling compounds in plants. Oxidative stress may lead to single strand breaks (SSB) in DNA, which activate poly(ADP‐ribose) polymerase (PARP). NIC and NIA are then formed from NAD. NIC and NIA can promote epigenetic changes leading to the expression of defense genes specific for the ...
Torkel Berglund, Anna B. Ohlsson
wiley   +1 more source

Impact of the tissue factor pathway inhibitor gene on apoptosis in human vascular smooth muscle cells

open access: yesGenetics and Molecular Biology, 2011
Tissue factor pathway inhibitor (TFPI) plays a vitally important role in the blood coagulation pathway. Recent studies indicated that TFPI induces apoptosis in vascular smooth-muscle cells (VSMCs) in animals.
Xia Dong   +5 more
doaj   +1 more source

Microenvironment and tumor cells: two targets for new molecular therapies of hepatocellular carcinoma. [PDF]

open access: yes, 2018
Hepatocellular carcinoma (HCC), is one of the most frequent human cancer and is characterized by a high mortality rate. The aggressiveness appears strictly related to the liver pathological background on which cancer develops.
Amicone, Laura, Marchetti, Alessandra
core   +1 more source

Imeglimin attenuates liver fibrosis by inhibiting vesicular ATP release from hepatic stellate cells

open access: yesFEBS Letters, EarlyView.
Imeglimin, at clinically relevant concentrations, inhibits vesicular ATP accumulation and release from hepatic stellate cells, thereby attenuating purinergic signaling and reducing fibrogenic activation. This mechanism reveals a newly identified antifibrotic action of imeglimin beyond glycemic control.
Seiji Nomura   +8 more
wiley   +1 more source

Prothrombotic profile in patients with vasospastic or non vasospastic angina and non significant coronary stenosis

open access: yesThrombosis Journal, 2011
Background Patients with vasospastic (VA) or non vasospastic angina (NVA) without significant coronary stenosis have a reduced risk of infarction but is unclear whether or not this may be attributable to a lack of prothrombotic profile - similar to that ...
Garcia-Dorado David   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy